Table 1.
Baseline characteristics LT patients by vaccination status.
| Unvaccinated group (n = 1394) | Vaccinated group (n = 487) | P value | |
|---|---|---|---|
| Number of patients, n (%) | |||
| Shanghai Huashan Hospital | 760 (75.8) | 243 (24.2) | |
| Beijing Friendship Hospital | 276 (71.7) | 109 (28.3) | |
| The first hospital of Jilin University | 212 (71.4) | 85 (28.6) | |
| Shanghai Changhai Hospital | 80 (79.2) | 21 (20.8) | |
| Shanghai first people’s hospital | 31 (79.5) | 8 (20.5) | |
| Shanghai Ruijin Hospital | 16 (59.3) | 11 (40.7) | |
| Shanghai Changzheng Hospital | 19 (65.5) | 10 (34.5) | |
| Number of patients, n (%) | |||
| Shanghai | 171 (78.4) | 47 (21.6) | |
| Beijing | 60 (66.7) | 30 (33.3) | |
| Changchun | 115 (68.0) | 54 (32.0) | |
| Others | 1048 (74.6) | 356 (25.4) | |
| Age (years), mean ± SD | 42.1 ± 21.6 | 45.2 ± 19.3 | 0.003 |
| Gender, Male (%) | 990 (71.0) | 371 (76.2) | 0.028 |
| Comorbidity, n (%) | |||
| Diabetes | 237 (17.0) | 74 (15.2) | 0.356 |
| Hypertension | 202 (14.5) | 70 (14.4) | 0.950 |
| Hyperlipidemia | 88 (6.3) | 41 (8.4) | 0.113 |
| Hyperuricemia | 143 (10.3) | 54 (11.1) | 0.607 |
| Cerebrovascular disease | 28 (2.0) | 4 (0.8) | 0.123 |
| Cardiovascular disease | 28 (2.0) | 16 (3.3) | 0.109 |
| Respiratory diseases | 22 (1.6) | 11 (2.3) | 0.325 |
| Rheumatic immune disease | 6 (0.4) | 2 (0.4) | 1.000 |
| Renal diseases | 37 (2.7) | 10 (2.1) | 0.465 |
| Hematological diseases | 10 (0.7) | 1 (0.2) | 0.352 |
| Hypoleukocytemia | 56 (4.0) | 12 (2.5) | 0.114 |
| Malignant tumour, n (%) | 318 (22.8) | 126 (25.9) | 0.171 |
| Prognosis of malignant tumour, n (%) | |||
| Recurrence and metastasis-free | 235 (73.9) | 107 (84.8) | 0.013 |
| Intrahepatic recurrence | 49 (15.4) | 10 (7.9) | |
| Pulmonary metastasis | 22 (6.9) | 4 (3.2) | |
| Osseous metastasis | 11 (3.5) | 0 (0) | |
| Other | 16 (5.0) | 9 (7.1) | |
| Targeted/chemotherapeutic drugs, n (%) | 132 (56.1) | 38 (30.2) | 0.027 |
| Vaccination status, n (%) | |||
| Partially vaccinated | 38 (7.8) | ||
| Fully vaccinated | 286 (58.7) | ||
| Booster vaccinated | 163 (33.5) | ||
| Vaccine type, n (%) | |||
| Inactivated vaccine | 479 (98.4) | ||
| Recombinant protein vaccine | 9 (1.8) (1 as Booster) | ||
| Adenovirus vaccine | 1 (0.2) (1 as Booster) | ||
| Duration of initial inoculation to LT | |||
| Preoperative, n (%) | 119 (24.4) | ||
| Postoperative, n (%) | 368 (75.6) | ||
| Infection rate (%) | |||
| Overall | 0.8 | 0.6 | 0.939 |
| With Malignant tumour | 1.3 | 0.8 | 0.676 |
| Without Malignant tumour | 0.7 | 0.6 | 0.841 |
| With Targeted/chemotherapeutic drugs | 0.2 | 0.3 | 0.534 |
| Without Targeted/chemotherapeutic drugs | 0.1 | 0 | 0.829 |
| Preoperative vaccination | 1.7 | ||
| Postoperative vaccination | 0.3 | ||
n: number; SD: standard deviation.